KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Weighted Average) (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $11.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) changed 0.3% year-over-year to $11.6 million, compared with a TTM value of $11.6 million through Sep 2025, changed 0.3%, and an annual FY2024 reading of $11532.0, up 10.45% over the prior year.
  • Shares Outstanding (Weighted Average) was $11.6 million for Q3 2025 at TherapeuticsMD, roughly flat from $11.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $422.2 million in Q3 2021 and bottomed at $10441.0 in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $70.9 million, with a median of $11.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 54.9% in 2021, then tumbled 99.88% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $422.2 million in 2021, then plummeted by 97.86% to $9.0 million in 2022, then crashed by 99.88% to $10441.0 in 2023, then rose by 10.45% to $11532.0 in 2024, then soared by 100203.5% to $11.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TXMD at $11.6 million in Q3 2025, $11.6 million in Q2 2025, and $11.6 million in Q1 2025.